82 FR 28493 - Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access; Public Meeting; Request for Comments
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 82, Issue 119 (June 22, 2017)
Food and Drug Administration
Federal Register Volume 82, Issue 119 (June 22, 2017)
| Page Range | 28493-28496 | |
| FR Document | 2017-12641 |
[Federal Register Volume 82, Number 119 (Thursday, June 22, 2017)] [Notices] [Pages 28493-28496] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-12641] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-N-3615] Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access; Public Meeting; Request for Comments AGENCY: Food and Drug Administration, HHS. ACTION: Notice of public meeting; request for comments. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA or the Agency) is announcing the following meeting: ``The Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access.'' This public meeting is intended to provide the public an opportunity to submit comments concerning administration of the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act) to help ensure the intended balance between encouraging innovation in drug development and accelerating the availability to the public of lower cost alternatives to innovator drugs is maintained. DATES: The meeting will be held on July 18, 2017, from 9 a.m. to 5 p.m. The deadline for submitting comments regarding this meeting is September 18, 2017. ADDRESSES: The meeting will be held at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993. Entrance for the public meeting participants (non-FDA employees) is through Building 1, where routine security check procedures will be performed. For parking and security information, please refer to http://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm. You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before September 18, 2017. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of September 18, 2017. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. Electronic Submissions Submit electronic comments in the following way: [[Page 28494]]Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ``Written/Paper Submissions'' and ``Instructions''). Written/Paper Submissions Submit written/paper submissions as follows: Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ``Instructions.'' Instructions: All submissions received must include the Docket No. FDA-2017-N-3615 for ``Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access; Public Meeting; Request for Comments.'' Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ``confidential.'' Any information marked as ``confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.thefederalregister.org/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ``Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Philip Bonforte, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1668, Silver Spring, MD 20993, 240-402- 6980, email: [email protected]. SUPPLEMENTARY INFORMATION: I. Background With the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) (Hatch-Waxman Amendments), Congress intended to strike a balance between encouraging innovation in drug development and accelerating the availability to the public of lower cost alternatives to innovator drugs. See H.R. Rep. No. 98-857 (Part I), 98th Cong, 2d Sess. At 14-15 (1984), reprinted in 1984 U.S.C.C.A.N. 2647-48; see also, e.g., Teva Pharmaceutical Industries Ltd. v. Crawford, 410 F.3d 51, 54 (D.C. Cir. 2005). To provide incentives intended to encourage the development of innovative new drugs and new uses of approved drugs, the Hatch-Waxman Amendments provided sponsors of innovator drugs with exclusivity and protections based on patent listings that protect certain aspects of innovator drugs from generic competition for certain periods of time. To ensure the availability of generic drugs, the Hatch-Waxman Amendments created an abbreviated new drug application (ANDA) process that allows sponsors of generic drugs to rely on the Agency's finding of safety and effectiveness for innovator drugs in seeking approval of their generic products after patent or marketing exclusivity protections held by the innovator expire or are otherwise removed. FDA's generic drug program has dramatically expanded access to quality, affordable generic medicines. According to the IMS Institute for Healthcare Informatics, generic drugs saved the U.S healthcare system $1.68 trillion from 2005-2014.\1\ --------------------------------------------------------------------------- \1\ IMS Health Institute for Healthcare Informatics (April 2015), available at http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports. --------------------------------------------------------------------------- Over the past several years, the Agency has undertaken major initiatives to expand access to quality, affordable generic medicines. For example, pursuant to the Generic Drug User Fee Amendments of 2012 (GDUFA I), FDA modernized the ANDA review program, and adopted metric goals to promote timely and predictable ANDA review. As a result, in Fiscal Year 2016, combined ANDA approvals and tentative approvals reached record highs. Pursuant to the proposed GDUFA II,\2\ FDA would further enhance the ANDA review program by clarifying regulatory expectations early in product development, helping applicants develop more complete submissions, and giving applicants more opportunities to address deficiencies within a review cycle, all with the goal of reducing the number of review cycles necessary to obtain ANDA approval. --------------------------------------------------------------------------- \2\ GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2018-2022 (October 2016), available at https://www.fda.gov/downloads/forindustry/userfees/genericdruguserfees/ucm525234.pdf. --------------------------------------------------------------------------- The development and approval of an innovator drug, and the subsequent approval and marketing of a generic version, together make up the life cycle of that drug product as contemplated by the Hatch- Waxman Amendments. At the front end of the life cycle, innovation in drug products-- including improvements to approved innovator drug products--provides life-changing and oftentimes life-saving therapeutic benefits to patients. In enacting the Hatch-Waxman Amendments, Congress recognized the importance of providing incentives to develop new products, and [[Page 28495]] new conditions of use for approved products. To further incentivize innovation, Congress subsequently established additional incentives in the form of exclusivity periods for drug products studied in pediatric populations, rare diseases, and new antibiotic treatments. Congress also provided a period of 180-day exclusivity for certain first generic applications as an incentive for generic manufacturers to challenge patents on innovator drugs that might otherwise prevent approval or delay generic entry into the market. These exclusivities, which are generally designed to reward sponsors with finite periods of limited or no generic or follow-on competition, were intended to expand the availability of safe and effective medicines for which insufficient or no treatment previously existed or to encourage generic drug development that might not have been profitable otherwise. In some cases, however, the legal framework surrounding these exclusivities may have been applied to delay generic competition to an extent that may not have been intended by the Hatch-Waxman Amendments, and in ways that may not serve the public health. Relatedly, certain elements of the approval process for both innovator and generic drugs have been used in ways that may (depending on the circumstances) inappropriately hinder generic competition. For example, innovators in some cases have made late changes in patent use codes that create new obstacles to previously acceptable labeling carve-outs. The entry of generic products to the marketplace is also affected by factors external to regulation under the FD&C Act--e.g., the outcome of private party patent litigation, and commercial decisions not to market approved innovator or generic products. In other cases, restrictions on the distribution of innovator drug products, whether voluntarily adopted by the innovator or imposed as a requirement of FDA regulation, have prevented developers from accessing the product samples needed for testing to support ANDAs or other follow-on applications. FDA will hold a public meeting on July 18, 2017, 9 a.m. to 5 p.m., to provide an opportunity for all interested stakeholders to submit comments concerning the appropriate balance between encouraging innovation in drug development and accelerating the availability to the public of lower cost alternatives to innovator drugs. The format of the meeting involves presentations from the public only. The Agency will not be inviting specific presenters; rather, with this document, FDA is soliciting presentations from interested stakeholders. FDA also invites interested persons to submit written comments to the docket on the topics described in section II. II. Topics for This Public Meeting FDA is soliciting input from the public concerning how best to preserve the balance Congress intended to strike in the Hatch-Waxman Amendments between encouraging innovation in drug development and accelerating the availability to the public of lower cost alternatives to innovator drugs. Preserving this balance is critical to the public health, and innovators, generic drug manufacturers, and FDA (among others) all have a role to play in maintaining it. This public meeting is part of an effort to create a broader understanding of the interplay between the existing legal and regulatory framework, available incentives and marketplace practices, and consumer access to generic drugs. The Agency welcomes any relevant information that stakeholders wish to share. We are particularly interested in stakeholder input on the following questions: 1. How has the balance struck in the Hatch-Waxman Amendments been affected by practices and trends related to the following: a. Exclusivity periods, b. Patents (including patent listing procedures), c. Innovator drug product labeling, d. Post-approval changes to innovator drug products, e.g., reformulations, and e. Other regulatory processes, including the citizen petition process? 2. The drugs described in more than half of all FDA-approved ANDAs are never marketed, marketed only after a substantial delay after approval, or marketed only intermittently. Such failures to market contribute to drug shortages, and hinder consumer access to approved products. What marketplace dynamics dis-incentivize the marketing of approved generic products? What should FDA do, within its statutory authority, to help more approved generics reach consumers? 3. For approximately 10 percent of all innovator drugs, patent and exclusivity protections have expired, but FDA has not received an ANDA. Are there market niches where the Hatch-Waxman Amendments incentives to develop an ANDA are insufficient? Similarly, are there niches where the incentives are insufficient to seek new drug approval of a marketed unapproved drug product that in turn could serve as a Reference Listed Drug? What should FDA do, consistent with its legal authority, to encourage submission development in any such market niches? 4. The statutory requirement that Risk Evaluation and Mitigation Strategies (REMS) that include elements to assure safe use (ETASU) be implemented through a ``single shared system'' relies on brand and generic companies agreeing on such a system before generic drugs may come to market. In some cases, challenges in reaching such an agreement between the parties may cause delays to generic competition. How should FDA apply its statutory authority to waive this requirement to implement a ``single shared system,'' or develop other administrative tools, to avoid these delays? 5. Restrictions on distribution, either required by innovators or as part of a REMS ETASU, can prevent generic companies from obtaining drug products for bioequivalence and other testing to support ANDA submissions. FDA published a draft guidance for industry, entitled ``How to Obtain a Letter from the Food and Drug Administration Stating That Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable Risk and Evaluation Mitigation Studies for Reference Listed Drugs,'' in December 2014. Despite this draft guidance, generic companies have reported continuing difficulties obtaining sufficient samples of drug products for testing. What additional actions should FDA take, within its legal authority, to promote access to these drug products for generic companies seeking to conduct studies required to support ANDA submissions? 6. What other elements of drug product development, regulation, and marketing have the potential to disrupt the Hatch-Waxman Amendments' balance between innovation and generic availability, and how should the Agency and other stakeholders address them? Registration and Requests for Oral Presentations: Send registration information (including name, title, firm name, address, telephone, email address, and fax number), and written material and requests to make oral presentations, to the contact person by July 3, 2017. If you need special accommodations due to a disability, please contact Philip Bonforte (see FOR FURTHER INFORMATION CONTACT) at least 7 days in advance. Transcripts: Please be advised that as soon as a transcript is available, it will be accessible at https://www.regulations.gov. It may be viewed at the Dockets Management Staff (see ADDRESSES). [[Page 28496]] Dated: June 14, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. [FR Doc. 2017-12641 Filed 6-21-17; 8:45 am] BILLING CODE 4164-01-P
![Federal Register / Vol. 82, No. 119 / Thursday, June 22, 2017 / Notices 28493
other stakeholder feedback and type of potentially violative promotional violations of the Tobacco Control Act
notification of potential violations of the materials; who potentially violated; and through the following methods: Calling
FD&C Act, as amended by the Tobacco the name, address, phone number, and the Tobacco Call Center using the
Control Act. email address of the potential violator. Center for Tobacco Products’ (CTP) toll-
FDA created a Tobacco Call Center The caller will also be asked to list the free number; using a fillable Form FDA
(with a toll-free number: 1–877–CTP– potential violator’s Web site (if 3779 found on FDA’s Web site;
1373). Callers are able to report available), describe the potential downloading a PDF version of the form
potential violations of the Tobacco violation, and provide any additional to send via email or mail to FDA;
Control Act, and FDA may conduct files or information pertinent to the requesting a copy of Form FDA 3779 by
followup investigations based on potential violation. contacting CTP and sending by mail to
information received. When callers FDA currently provides a form that FDA; and sending a letter to FDA’s CTP.
report a violation, the caller will be may be used to solicit this information In the Federal Register of November
asked to provide as much certain from the caller (Form FDA 3779, 7, 2016 (81 FR 78166), FDA published
information as they can recall, Potential Tobacco Product Violations a 60-day notice requesting public
including: The date the potential Report), and seeks renewal of Form FDA comment on the proposed collection of
violation occurred; product type (e.g., 3779. This form is posted on FDA’s Web information. No comments were
cigarette, smokeless, roll-your-own, site. The public and interested received.
cigar, e-cigarette, hookah, pipe tobacco); stakeholders are also able to report FDA estimates the burden of this
tobacco brand; potential violation type; information regarding possible collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
Number of Total annual Average burden
Activity and FDA Form 3779 responses per Total hours
respondents responses per response
respondent
Reporting violations of the FD&C Act, as 750 2 1,500 0.25 (15 minutes) ........... 375
amended by the Tobacco Control Act via tele-
phone, Internet form, mail, smartphone appli-
cation, or email.
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
FDA estimates that submitting the DEPARTMENT OF HEALTH AND regarding this meeting is September 18,
information (by telephone, Internet HUMAN SERVICES 2017.
form, paper form by mail, or email) will ADDRESSES: The meeting will be held at
take 0.25 hour (i.e., 15 minutes) per Food and Drug Administration the FDA White Oak Campus, 10903
response. Based on the type and rate of [Docket No. FDA–2017–N–3615] New Hampshire Ave., Bldg. 31
reporting that has been submitted Conference Center, the Great Room (Rm.
through the Potential Tobacco Violation Administering the Hatch-Waxman 1503), Silver Spring, MD 20993.
Reporting Form in the past, in addition Amendments: Ensuring a Balance Entrance for the public meeting
to the increase that FDA has recently Between Innovation and Access; participants (non-FDA employees) is
experienced in the rate of reporting due Public Meeting; Request for Comments through Building 1, where routine
to the recent rule, ‘‘Deeming Tobacco security check procedures will be
AGENCY: Food and Drug Administration, performed. For parking and security
Products To Be Subject to the Federal
HHS. information, please refer to http://
Food, Drug, and Cosmetic Act, as
Amended by the Family Smoking ACTION: Notice of public meeting; www.fda.gov/AboutFDA/
Prevention and Tobacco Control Act,’’ request for comments. WorkingatFDA/BuildingsandFacilities/
FDA estimates the number of annual WhiteOakCampusInformation/
SUMMARY: The Food and Drug ucm241740.htm.
respondents to this collection of Administration (FDA or the Agency) is
information will be 750, who will each You may submit comments as
announcing the following meeting: ‘‘The follows. Please note that late, untimely
submit 2 reports by telephone, Internet Hatch-Waxman Amendments: Ensuring filed comments will not be considered.
form, paper form, or email. Each report a Balance Between Innovation and Electronic comments must be submitted
is expected to take 0.25 hour to Access.’’ This public meeting is on or before September 18, 2017. The
complete and submit; therefore, total intended to provide the public an https://www.regulations.gov electronic
burden hours for this collection of opportunity to submit comments filing system will accept comments
information is estimated to be 375 hours concerning administration of the Hatch- until midnight Eastern Time at the end
(1,500 responses x 0.25 hour per Waxman Amendments to the Federal of September 18, 2017. Comments
response). Food, Drug, and Cosmetic Act (FD&C received by mail/hand delivery/courier
Act) to help ensure the intended balance (for written/paper submissions) will be
Dated: June 12, 2017.
between encouraging innovation in drug
sradovich on DSK3GMQ082PROD with NOTICES
Anna K. Abram, considered timely if they are
development and accelerating the postmarked or the delivery service
Deputy Commissioner for Policy, Planning, availability to the public of lower cost
Legislation, and Analysis. acceptance receipt is on or before that
alternatives to innovator drugs is date.
[FR Doc. 2017–13018 Filed 6–21–17; 8:45 am] maintained.
BILLING CODE 4164–01–P Electronic Submissions
DATES: The meeting will be held on July
18, 2017, from 9 a.m. to 5 p.m. The Submit electronic comments in the
deadline for submitting comments following way:
VerDate Sep<11>2014 16:08 Jun 21, 2017 Jkt 241001 PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 E:\FR\FM\22JNN1.SGM 22JNN1](https://thefederalregister.org/doc/82_FR_28612/page/1.svg)
![28496 Federal Register / Vol. 82, No. 119 / Thursday, June 22, 2017 / Notices
Dated: June 14, 2017. officer for HRSA, either by email to strengthen the rural health care system
Anna K. Abram, OIRA_submission@omb.eop.gov or by as a whole.
Deputy Commissioner for Policy, Planning, fax to 202–395–5806. Need and Proposed Use of the
Legislation, and Analysis. FOR FURTHER INFORMATION CONTACT: To Information: Performance measures for
[FR Doc. 2017–12641 Filed 6–21–17; 8:45 am] request a copy of the clearance requests the Network Planning program serve the
BILLING CODE 4164–01–P submitted to OMB for review, email the purpose of quantifying awardee-level
HRSA Information Collection Clearance data that conveys the successes and
Officer at paperwork@hrsa.gov or call challenges associated with the grant
DEPARTMENT OF HEALTH AND (301) 443–1984. award. These measures and aggregate
HUMAN SERVICES data substantiate and inform the
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting objectives of the program. The approved
Health Resources and Services
information, please include the measures encompass the following
Administration
information request collection title for principal topic areas: network
Agency Information Collection reference, in compliance with Section infrastructure, network collaboration,
Activities: Submission to OMB for 3506(c)(2)(A) of the Paperwork sustainability, and network assessment.
Review and Approval; Information Reduction Act of 1995. Likely Respondents: The respondents
Collection Request Title: Rural Health Information Collection Request Title: for these measures are Network
Network Development Planning Rural Health Network Development Planning award recipients.
Performance Improvement and Planning Performance Improvement and Burden Statement: Burden in this
Measurement System Database, OMB Measurement System Database, OMB context means the time expended by
No. 0915–0384—Extension No. 0915–0384—Extension. persons to generate, maintain, retain,
AGENCY: Health Resources and Services Abstract: The purpose of the Rural disclose, or provide the information
Administration (HRSA), Department of Health Network Development Planning requested. This includes the time
Health and Human Services. (Network Planning) program is to assist needed to review instructions; to
ACTION: Notice. in the development of an integrated develop, acquire, install, and utilize
health care network, specifically for technology and systems for the purpose
SUMMARY: In compliance with the entities that do not have a history of of collecting, validating and verifying
Paperwork Reduction Act of 1995, formal collaborative efforts. Health care information, processing and
HRSA has submitted an Information networks can be an effective approach maintaining information, and disclosing
Collection Request (ICR) to the Office of to help smaller rural health care and providing information; to train
Management and Budget (OMB) for providers and health care service personnel and to be able to respond to
review and approval. Comments organizations align resources, achieve a collection of information; to search
submitted during the first public review economies of scale and efficiency, and data sources; to complete and review
of this ICR will be provided to OMB. address challenges more effectively as a the collection of information; and to
OMB will accept further comments from group than as single providers. The transmit or otherwise disclose the
the public during the review and Network Planning program promotes information. The total annual burden
approval period. the planning and development of hours, which are unchanged from the
DATES: Comments on this ICR should be healthcare networks to: (1) Achieve currently approved form, are
received no later than July 24, 2017. efficiencies; (2) expand access to, summarized in the table below.
ADDRESSES: Submit your comments, coordinate, and improve the quality of Total Estimated Annualized Burden
including the ICR Title, to the desk essential health care services; and (3) Hours:
Average
Number of
Number of Total burden per Total
Form name responses per
respondents responses response burden hours
respondent (in hours)
Rural Health Network Development Planning Program
Performance Improvement Measurement System .......... 21 1 21 1 21
Total .............................................................................. 21 ........................ 21 ........................ 21
Jason E. Bennett, announces the following special the advisory body to the U.S.
Director, Division of the Executive Secretariat. workgroup activity. Department of Health and Human
[FR Doc. 2017–13019 Filed 6–21–17; 8:45 am] Name: National Committee on Vital Services (HHS) Secretary on health data,
BILLING CODE 4165–15–P and Health Statistics (NCVHS), statistics, privacy, and national health
Subcommittee on Standards Meeting. information policy. NCVHS’ role
Date and Time: Monday, August 21, includes advising HHS in the
DEPARTMENT OF HEALTH AND 2017: 9:00 a.m.–4:00 p.m. implementation of the Administrative
HUMAN SERVICES Place: U.S. Department of Health and Simplification provisions of the Health
sradovich on DSK3GMQ082PROD with NOTICES
Human Services, Hubert H. Humphrey Insurance Portability and
National Committee on Vital and Health Building, 200 Independence Avenue Accountability Act of 1996 (HIPAA) and
Statistics: Meeting SW., Room 800, Washington, DC 20201, the Patient Protection and Affordable
(202) 690–7100. Care Act of 2010 (ACA). The Standards
Pursuant to the Federal Advisory Status: Open. Subcommittee of NCVHS makes
Committee Act, the Department of Purpose: The National Committee on recommendations to the full Committee
Health and Human Services (HHS) Vital and Health Statistics (NCVHS) is on health data standards, including
VerDate Sep<11>2014 16:08 Jun 21, 2017 Jkt 241001 PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 E:\FR\FM\22JNN1.SGM 22JNN1](https://thefederalregister.org/doc/82_FR_28612/page/4.svg)
Document Created: 2017-06-21 23:55:38
Document Modified: 2017-06-21 23:55:38
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice of public meeting; request for comments. | |
| Dates | The meeting will be held on July 18, 2017, from 9 a.m. to 5 p.m. The deadline for submitting comments regarding this meeting is September 18, 2017. | |
| Contact | Philip Bonforte, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1668, Silver Spring, MD 20993, 240-402- 6980, email: [email protected] | |
| FR Citation | 82 FR 28493 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR